Heartseed (219A) Fundamentals 2026 — P/E 35.9x, Revenue Analysis | SniperIQ
Heartseed (219A) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥36.9B, trading at ¥1614.00 on the JPX. This SniperIQ fundamentals page covers Heartseed's valuation (P/E 35.9x, P/B 5.2x), profitability (net margin 29.0%), revenue (¥3.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Heartseed's market cap?
Heartseed (219A) has a market capitalization of approximately ¥36.9B, trading at ¥1614.00 on the JPX. Market cap moves with the live share price.
What is Heartseed's P/E ratio?
Heartseed's trailing twelve-month P/E ratio is 35.9x, with a price-to-book (P/B) of 5.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Heartseed?
Heartseed runs a net profit margin of 29.0%, a gross margin of 86.9%, and an operating margin of 18.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Heartseed generate?
Heartseed reported revenue of ¥3.0B for fiscal year 2025, with net income of ¥163M and earnings per share (EPS) of 7.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Heartseed pay a dividend?
Heartseed does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Heartseed financially healthy?
Heartseed carries a debt-to-equity ratio of 0.00x and a current ratio of 23.23x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Heartseed a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Heartseed (219A) the key facts are: market cap ¥36.9B, P/E 35.9x, revenue ¥3.0B, 52-week range 1343-3925. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Heartseed's full fundamentals live
Get Heartseed's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.